Alterity Therapeutics Limited American Depositary Shares (ATHE)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style exercise in separating a speculative clinical story from an investment. Alterity is a healthcare biotechnology company with 11 employees, developing ATH434 for Parkinsonian disorders and MSA. The lead candidate has completed Phase II in Parkinson's, and related Phase II programs are underway. That is a long way from a moat; there is no revenue growth or profit growth data provided, and the only visible competitive asset is the pipeline itself. Financial health is weak. On the 2026-10-13 close of $2.85, market cap is $82.3M. The FairStock P/E is -3.00, P/B 1.70, ROE -54.98%, ROCE -34.08%, and Piotroski F-Score 0/9. The one bright spot is a debt-to-equity of 0.00 and an Altman Z-Score of 8.62, which by that measure suggests low bankruptcy risk, though a clinical-stage company can still consume cash. The negative beta of -0.04 is unusual but not a margin of safety. Valuation is difficult. A negative P/E means there are no earnings to capitalize. P/B of 1.70 offers no obvious asset discount. The 52-week range is $2.66-$5.89, so the price is near the low, but cheapness must be measured against earning power, which is absent. FairStock Score 36/100 and no Lynch category - because only 0 years of filed results are available versus the required 3 - underline the lack of history. Growth, if it comes, will be binary and trial-driven. I would need filed revenue and profit data, plus successful Phase II results, before calling this a business rather than an option.

In plain English: Alterity Therapeutics is a small clinical-stage biotech with about 11 employees. It is developing drugs for Parkinson's disease and a related disorder called multiple system atrophy, with its main candidate in mid-stage human testing. The business looks weak financially today: it loses money, has negative returns, and no reported revenue growth. At $2.85, the price is near the low end of its 52-week range, but without profits it is hard to call it cheap or expensive on business results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer